FDAnews Drug Daily Bulletin

VERNALIS BUYS RIGHTS TO PARKINSON DISEASE DRUG APOKYN FOR 23 MLN USD

Nov. 7, 2005
A A

Drug developer, Vernalis PLC said it has bought the exclusive rights in North America to marketed product for advanced Parkinson's Disease, Apokyn from Mylan for a one-off cash payment of 23 mln usd. Apokyn was approved by the FDA as an Orphan Drug in April 2004, launched in the US in July 2004 and has market exclusivity until 2011. Vernalis estimates sales of Apokyn in North America in 2006 will be in the range of 6-7.5 mln usd.

Forbes (http://www.forbes.com/home/feeds/afx/2005/11/04/afx2318357.html%20)